DATE/TIME
September 24, 02:00 – 02:30 PM EST
TOPIC
The Biomanufacturing Capacity Crunch: Where CDMO Demand Is Still Outrunning Supply
SPEAKER
Eric Langer, President and Managing Partner, BioPlan Associates, Inc.
ABSTRACT
Biopharma companies continue to rely on CDMOs for development and manufacturing support, but many sponsors still struggle to find the right capacity at the right time. Drawing on BioPlan’s latest industry survey data, this session will examine where capacity constraints remain most acute, including mammalian production, microbial fermentation, cell therapy and gene therapy. Eric Langer will discuss what is driving the imbalance, how CDMOs are expanding, and why sponsors are looking beyond open manufacturing slots to evaluate flexibility, technical expertise, responsiveness and long-term fit
BIO
Eric Langer has more than 25 years of experience in life sciences market assessment, valuation, marketing and strategy. He has advised hundreds of biopharma and bioprocessing companies on market trends, buyer needs, pricing, messaging and strategic planning. Langer’s team has long evaluated contract and outsourced bioprocessing services, including discovery, bioproduction, assay development and fill-finish. He has authored numerous articles and book chapters on outsourcing, supply chain security and service technologies, and BioPlan has developed CDMO market databases and supplier resources for more than 20 years.
